As part of a four-part series, we are looking at targeted delivery in idiopathic pulmonary fibrosis (IPF). This week, we focus on inhalation therapy after following with interest the progress of the inhaled formulation of pirfenidone (AP01, Avalyn Pharma). This approach delivers high concentrations of a drug already established as an effective oral therapy in […]
We’d like to send you our company updates, invites to events and any other relevant news. By providing your details and subscribing to this list, you are giving us your consent to send you these updates.
We’ll always be mindful of how often we send our updates and you can amend your preferences at any time.
We’ll never sell or swap your data with any organisation and we’ll store your details securely, respecting your trust and privacy. Please view our privacy policy for further details.
